+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

mRNA Platform Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • TechSci Research
  • ID: 5900217
Free Webex Call
10% Free customization
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The mRNA Platform Market was valued at USD 7.30 Billion in 2024 and is projected to reach USD 8.93 Billion by 2030, rising at a CAGR of 3.56%. The mRNA (messenger RNA) platform is an advanced biotechnological innovation that enables synthetic RNA molecules to deliver genetic instructions to cells, prompting the production of specific proteins. This approach has demonstrated significant success in vaccine development and is expanding into treatments for a range of diseases.

Notably, in September 2023, BioNTech SE partnered with CEPI to accelerate the development of an mRNA-based Mpox vaccine, underscoring the platform’s importance in preparing for emerging infectious threats. By mimicking the natural role of RNA in the body, synthetic mRNA sequences are engineered to prompt immune responses or support therapeutic protein production. These technologies are increasingly adopted due to their adaptability, speed of development, and effectiveness, particularly in public health emergencies and personalized medicine applications.

Key Market Drivers

Technological Advancements

Advances in lipid nanoparticle (LNP) delivery systems have enhanced the stability and cellular uptake of mRNA molecules, improving their efficacy. These innovations were instrumental in the success of COVID-19 mRNA vaccines. Modified mRNA sequences are now more stable and less immunogenic, extending vaccine shelf life and easing distribution. For example, Sanofi launched a new mRNA research facility at Griffith University in November 2023 to accelerate drug development.

Techniques like codon optimization are being refined to maximize protein expression, while synthetic biology tools such as CRISPR-Cas9 allow precise mRNA sequence design for targeted therapies. The development of cost-efficient and scalable manufacturing has also improved the availability of mRNA products during global health crises. Furthermore, enhancements in cold chain logistics and stability at varied temperature ranges reduce dependency on ultra-cold storage. The integration of next-generation sequencing supports precise and rapid design of mRNA-based treatments, enabling therapeutic applications across a broad range of indications.

Key Market Challenges

Vaccine Hesitancy and Misinformation

A critical challenge facing the Global mRNA Platform Market is vaccine hesitancy, fueled by misinformation. Despite scientific validation, concerns around safety, efficacy, and long-term impacts have hindered vaccine uptake. Social media platforms are often sources of misinformation, influencing public perception and eroding confidence in mRNA-based vaccines. This hesitancy can reduce immunization rates, hampering efforts to achieve herd immunity and prolonging outbreaks of preventable diseases. Public mistrust also complicates health campaigns during emergencies, such as pandemics, and may extend skepticism to other public health measures. Low vaccine coverage due to hesitancy not only affects individual health outcomes but also increases pressure on healthcare systems and obstructs disease control efforts at a population level.

Key Market Trends

Increase in the Number of Virtual Trials

The rise of virtual trials is reshaping drug development strategies, including those related to mRNA therapies. Virtual trials use digital platforms for remote data collection, reducing dependence on physical sites and expanding access to more diverse participant populations. CROs and pharmaceutical companies are increasingly adopting technologies such as telemedicine, wearable sensors, and mobile health apps to monitor patient outcomes in real-time. This approach enhances patient engagement, accelerates trial timelines, and reduces operational costs. The decentralized model is proving particularly effective for vaccines and therapies that require global outreach, supporting rapid data acquisition and streamlined regulatory submissions.

Key Players Profiled in this mRNA Platform Market Report

  • AstraZeneca PLC
  • Asuragen, Inc.
  • Catalent Pharma Solutions
  • Arcturus Therapeutics, Inc.
  • BioNTech AG
  • CRISPR Therapeutics Inc.
  • AKESOgen, Inc.
  • baseclick GmbH
  • Accent Therapeutics Inc.
  • Accanis Biotech F&E GmbH & Co KG

Report Scope:

In this report, the Global mRNA Platform Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

mRNA Platform Market, by Indication:

  • Autoimmune Diseases
  • Cancer
  • Personalized Treatment
  • Single Cancer Focused
  • Infectious Diseases
  • Rare Diseases
  • Respiratory Diseases

mRNA Platform Market, by Usability:

  • Prophylactic Vaccines
  • Therapeutic Drugs
  • Therapeutic Vaccines

mRNA Platform Market, by mRNA Type:

  • Nucleoside-Modified mRNA
  • Self-Amplifying mRNA
  • Unmodified mRNA

mRNA Platform Market, by End-User:

  • Hospitals & Clinics
  • Pharmaceutical Companies
  • Research Organization

mRNA Platform Market, by Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global mRNA Platform Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global mRNA Platform Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Indication (Autoimmune Diseases, Cancer, Infectious Diseases, Rare Diseases, Respiratory Diseases)
5.2.2. By Usability (Prophylactic Vaccines, Therapeutic Drugs, Therapeutic Vaccines)
5.2.3. By mRNA Type (Nucleoside-Modified mRNA , Self-Amplifying mRNA , Unmodified mRNA )
5.2.4. By End User (Hospitals & Clinics, Pharmaceutical Companies, Research Organization)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. Asia Pacific mRNA Platform Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Indication
6.2.2. By Usability
6.2.3. By mRNA Type
6.2.4. By End User
6.2.5. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China mRNA Platform Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Indication
6.3.1.2.2. By Usability
6.3.1.2.3. By mRNA Type
6.3.1.2.4. By End User
6.3.2. India mRNA Platform Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Indication
6.3.2.2.2. By Usability
6.3.2.2.3. By mRNA Type
6.3.2.2.4. By End User
6.3.3. Australia mRNA Platform Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Indication
6.3.3.2.2. By Usability
6.3.3.2.3. By mRNA Type
6.3.3.2.4. By End User
6.3.4. Japan mRNA Platform Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Indication
6.3.4.2.2. By Usability
6.3.4.2.3. By mRNA Type
6.3.4.2.4. By End User
6.3.5. South Korea mRNA Platform Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Indication
6.3.5.2.2. By Usability
6.3.5.2.3. By mRNA Type
6.3.5.2.4. By End User
7. Europe mRNA Platform Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication
7.2.2. By Usability
7.2.3. By mRNA Type
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. France mRNA Platform Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Indication
7.3.1.2.2. By Usability
7.3.1.2.3. By mRNA Type
7.3.1.2.4. By End User
7.3.2. Germany mRNA Platform Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Indication
7.3.2.2.2. By Usability
7.3.2.2.3. By mRNA Type
7.3.2.2.4. By End User
7.3.3. Spain mRNA Platform Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Indication
7.3.3.2.2. By Usability
7.3.3.2.3. By mRNA Type
7.3.3.2.4. By End User
7.3.4. Italy mRNA Platform Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Indication
7.3.4.2.2. By Usability
7.3.4.2.3. By mRNA Type
7.3.4.2.4. By End User
7.3.5. United Kingdom mRNA Platform Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Indication
7.3.5.2.2. By Usability
7.3.5.2.3. By mRNA Type
7.3.5.2.4. By End User
8. North America mRNA Platform Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication
8.2.2. By Usability
8.2.3. By mRNA Type
8.2.4. By End User
8.2.5. By Country
8.3. North America: Country Analysis
8.3.1. United States mRNA Platform Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Indication
8.3.1.2.2. By Usability
8.3.1.2.3. By mRNA Type
8.3.1.2.4. By End User
8.3.2. Mexico mRNA Platform Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Indication
8.3.2.2.2. By Usability
8.3.2.2.3. By mRNA Type
8.3.2.2.4. By End User
8.3.3. Canada mRNA Platform Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Indication
8.3.3.2.2. By Usability
8.3.3.2.3. By mRNA Type
8.3.3.2.4. By End User
9. South America mRNA Platform Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indication
9.2.2. By Usability
9.2.3. By mRNA Type
9.2.4. By End User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil mRNA Platform Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Indication
9.3.1.2.2. By Usability
9.3.1.2.3. By mRNA Type
9.3.1.2.4. By End User
9.3.2. Argentina mRNA Platform Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Indication
9.3.2.2.2. By Usability
9.3.2.2.3. By mRNA Type
9.3.2.2.4. By End User
9.3.3. Colombia mRNA Platform Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Indication
9.3.3.2.2. By Usability
9.3.3.2.3. By mRNA Type
9.3.3.2.4. By End User
10. Middle East and Africa mRNA Platform Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Indication
10.2.2. By Usability
10.2.3. By mRNA Type
10.2.4. By End User
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa mRNA Platform Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Indication
10.3.1.2.2. By Usability
10.3.1.2.3. By mRNA Type
10.3.1.2.4. By End User
10.3.2. Saudi Arabia mRNA Platform Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Indication
10.3.2.2.2. By Usability
10.3.2.2.3. By mRNA Type
10.3.2.2.4. By End User
10.3.3. UAE mRNA Platform Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Indication
10.3.3.2.2. By Usability
10.3.3.2.3. By mRNA Type
10.3.3.2.4. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global mRNA Platform Market: SWOT Analysis
14. Porter’s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. PESTLE Analysis
16. Competitive Landscape
16.1. Amgen Inc. AstraZeneca PLC
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (In case of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2. Asuragen, Inc.
16.3. Catalent Pharma Solutions
16.4. Arcturus Therapeutics, Inc.
16.5. BioNTech AG
16.6. CRISPR Therapeutics Inc.
16.7. AKESOgen, Inc.
16.8. Baseclick GmbH
16.9. Accent Therapeutics Inc.
16.10. Accanis Biotech F&E GmbH & Co KG
17. Strategic Recommendations18. About the Publisher & Disclaimer

Companies Mentioned

The leading companies profiled in this mRNA Platform market report include:
  • AstraZeneca PLC
  • Asuragen, Inc.
  • Catalent Pharma Solutions
  • Arcturus Therapeutics, Inc.
  • BioNTech AG
  • CRISPR Therapeutics Inc.
  • AKESOgen, Inc.
  • baseclick GmbH
  • Accent Therapeutics Inc.
  • Accanis Biotech F&E GmbH & Co KG

Table Information